Why choose
Medistus® Antivirus?

Medistus® Antivirus is a novel Class IIa medical device product ( 0481) with an active ingredient complex containing plant-based substances. The Kistosyn® 200 extract forms through its natural active substances a protective film over the oral and pharyngeal mucosa. This protective barrier leads to a physical (mechanical) protection against viruses and bacteria causing respiratory infections, which helps prevent their penetration into body cells and their further propagation.

Due to this physical effect resistance development is not possible.

Medistus antivirus

Protection on places with high risk of infection


Medistus Antivirus

Medistus® Antivirus

Lozenge with natural active ingredients, in fresh fruity taste

Medistus® Antivirus is a novel Class IIa medical device product ( 0481) with an active ingredient complex containing plant-based substances.

Medistus Antivirus

Medistus® Antivirus Honey Lemon

Lozenge with natural active ingredients, in honey & lemon taste

Medistus® Antivirus is a novel Class IIa medical device product ( 0481) with an active ingredient complex containing plant-based substances.


Respiratory infections

A common cold is usually a virus-induced, acute infection of the upper respiratory tract. This type of respiratory infections are among the most common diseases in modern industrial countries. On the average adults suffer up to five times a year a cold, preschoolers even eight to ten times. In most cases the infections are caused by viruses and associated with similar symptoms: shivering, sneezing, runny nose, cough and fatigue. Since antibiotics work only in the treatment of bacterial infections, applying them in case of infections of viral origin, they might remain ineffective.

Infection risks

Recently, infections by emerging viruses occur more frequently and they seem to be independent of seasons. These infections manifest themselves as fever from 38 °C and with symptoms such as sore throat, runny nose, cough, muscle and joint pains, headache and diarrhea.
Real influenza has to be dealt with separately from the other respiratory diseases related to cold. This infection is a disease caused by various types of influenza viruses and differs from other respiratory diseases both in its epidemiological, clinical characteristics and also in its impacts.

Penetration of viruses and bacteria in the body

Infections of the upper respiratory tract caused by viruses or bacteria will not necessarily lead to illness if the immune system is capable of effective defense against pathogens, or the pathogens are hindered at intruding the body by a barrier.
The main goal of a virus is to safeguard its own propagation for which it requires a host cell. To this end, it targets the cells in the oral mucosa and attempts to dock to them. In case of a successful attachment it penetrates the host cell membrane and reprograms it to promote its own multiplication.

Active defense
against infection

The research of the last decades has unambiguously demonstrated that in case of infection pathogens (viruses, bacteria) dock to the carbohydrate structures of the host cell membranes through their proteins based on the so-called key-lock principle. This process occurs in the oral and pharyngeal mucous membranes. In the event this docking process is successful, like a key opening a lock the pathogens penetrate the host cell and commence to multiply. The solution is compelling: we have to impede pathogens in docking to the host cells. 

Medistus Antivirus

Medistus® Antivirus lozenges

  • act as a protective film
  • form a natural barrier
  • assist preventively



  • To support by physical means the natural barrier function of the oral and pharyngeal mucosa against viruses and bacteria infecting the respiratory tract.
  • For the prevention of infectious and inflammatory airways diseases of viral and bacterial origin by physical (mechanical) barrier formation on the oral and pharyngeal mucosa.


  • In case of exposure to infections.
  • For protection at increased risk of airways infection of viral and bacterial origin.
  • Adults: Dissolve a lozenge slowly in the mouth 3 to 6 times a day.
  • Children older than 12 years (and at least 25 kg body weight): Dissolve a lozenge slowly in the mouth 3 times a day.
  • Children older than 6 years: Dissolve a lozenge slowly in the mouth once a day.

The lozenges may pose a choking risk for children when unable to dissolve them in the mouth. Please take particular care for children.

In case of taking medicines orally, please leave a pause of 2 hours in-between.


The production of Medistus® Antivirus lozenges takes place according to DIN EN ISO and GMP standards at the production site of a highly recognized pharmaceutical manufacturer in Germany using strictly controlled natural substances.

The license holder and the owner of the technical documentation of Medistus® Antivirus lozenges is the Innopharm GmbH in Austria.
The main activity of the company encompasses the trading and distribution of medical devices.
The Innopharm GmbH provides all necessary clinical studies and laboratory tests which are essential for the safety and efficacy of its medical devices. Furthermore, the Innopharm GmbH is the head of product development and innovation.

The exclusive rights for worldwide distribution are conferred upon the Vitaplus Kft in Hungary owing to its long-term experience and extensive network of commercial partners.
Medistus® Antivirus was introduced by Vitaplus Kft in numerous countries in Europe and in Overseas and has successfully been distributed there ever since.